多囊卵巢综合征患病率估计的差异:系统综述与Meta分析
该系统综述纳入21项研究,比较NIH、Rotterdam和AE-PCOS三种标准下PCOS的合并患病率。NIH标准为7%(95%CI:6-7%),Rotterdam标准为12%(95%CI:10-15%),两者差异显著(P<0.0001);AE-PCOS标准为10%(95%CI:6-13%),与NIH标准差异未达统计学显著(P=0.075),与Rotterdam标准亦无显著差异(P=0.201)。
要点
- Rotterdam标准合并患病率12%(95%CI:10-15%)显著高于NIH标准7%(95%CI:6-7%),P<0.0001。
- AE-PCOS标准合并患病率10%(95%CI:6-13%),与NIH标准(P=0.075)及Rotterdam标准(P=0.201)比较均无统计学显著差异。
- 稀发/无排卵定义、临床雄激素过多定义、F-G评分版本与切点、口服避孕药使用者纳入与否的亚组比较均无统计学显著差异。
核心结论
- 纳入卵巢形态学标准可导致PCOS合并患病率估计显著升高。
- 患病率估计的异质性反映了该病症广泛的临床谱、各诊断标准内部要素缺乏标准化、采用不同诊断切点以及研究人群间可能存在的差异。
- 稀发排卵和临床雄激素过多少的不同定义在本研究中似乎未导致PCOS估计患病率的差异。
- 由于多数比较组的研究数量少,可能遗漏了真实差异。
- PCOS诊断的不确定性亟需解决,以为临床医生及其患者提供更大的诊断确定性,从而减少不恰当 labeling 及误诊可能伴随的心理伤害。
研究设计与样本
- 系统检索Ovid MEDLINE、EMBASE、Cochrane Central Register of Controlled Trials(CENTRAL)、Emcare和BIOSIS,限英文文献,发表时间1990年1月至2018年1月。
- 纳入标准为:采用NIH、Rotterdam或AE-PCOS标准中至少一种定义PCOS、非选择人群、以全文形式发表。
- 共21项研究符合纳入标准,并进行了偏倚风险评估。
主要发现
- 采用NIH标准的研究中PCOS随机效应合并患病率为7%(95%CI:6-7%)。
- 采用Rotterdam标准的研究中PCOS合并患病率为12%(95%CI:10-15%),与NIH标准比较P<0.0001。
- 采用AE-PCOS标准的研究中PCOS合并患病率为10%(95%CI:6-13%),与NIH标准比较P=0.075。
- Rotterdam标准与AE-PCOS标准的合并估计值相互比较P=0.201。
- 按稀发/无排卵 vs 稀发/无排卵加短周期、需多毛症的临床雄激素过多 vs 任何临床雄激素过多、F-G评分不同版本与切点、口服避孕药使用者纳入 vs 不纳入进行亚组比较,均无统计学显著差异;卵巢多囊样定义因信息不足未能行亚组分析。
关键数值与推荐
- NIH标准合并患病率7%(95%CI:6-7%)。
- Rotterdam标准合并患病率12%(95%CI:10-15%)。
- AE-PCOS标准合并患病率10%(95%CI:6-13%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数比较组的研究数量少,可能遗漏了真实差异。
- 卵巢多囊样定义因信息不足未能进行亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic ovary syndrome (PCOS) prevalence estimates vary when different diagnostic criteria are applied. Lack of standardization of individual elements within these criteria may contribute to prevalence differences. OBJECTIVE AND RATIONALE: A systematic review of studies reporting prevalence of PCOS, using at least one of the National Institutes of Health (NIH), Rotterdam or Androgen Excess Society (AE-PCOS) criteria, was conducted. The aim was to investigate the impact on prevalence reporting of different definitions of the clinical elements for PCOS diagnosis. SEARCH METHODS: A systematic search of Ovid MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Emcare and BIOSIS was conducted. The search was limited to English language and studies published between January 1990 and January 2018. Included articles needed to define PCOS by at least one of the NIH, Rotterdam or AE-PCOS criteria, be of an unselected population and be published as a full text article. Risk-of-bias was assessed. OUTCOMES: A total of 21 studies met the inclusion criteria. The random-effects pooled prevalence of PCOS in studies that used the NIH criteria (7% [95% CI: 6-7%]), was significantly different from that identified in studies that used the Rotterdam criteria (12% [95% CI: 10-15%], P < 0.0001) but not studies that used the AE-PCOS criteria (10% [95% CI: 6-13%], P = 0.075). The pooled estimates for Rotterdam and AE-PCOS were not significantly different from each other (P = 0.201). Pooled prevalence estimates were compared between studies separated on the basis of: oligo-amenorrhoea vs oligo-amenorrhoea plus short cycles, clinical androgen excess requiring hirsutism vs any clinical androgen excess, use of different versions and cut-offs for the Ferriman-Gallwey (F-G) score, and inclusion vs non-inclusion of oral contraceptive users. There were no statistically significant differences for any of these comparisons. There was insufficient information to allow subgroup analyses of definitions of polycystic ovaries. WIDER IMPLICATIONS: Inclusion of ovarian morphology results in statistically significantly higher pooled prevalence estimates for PCOS. Heterogeneity in prevalence estimates for PCOS reflect the broad clinical spectrum of the condition, lack of standardization of the elements within each set of diagnostic criteria and the use of a range of diagnostic cut-offs, as well as potential differences between study populations. The use of different definitions for anovulation and clinical androgen excess did not appear to contribute to differences in the estimated prevalence of PCOS in this study. However, as the number of studies in most of the comparison groups was small, real differences may have been missed. Uncertainty surrounding the diagnosis of PCOS urgently needs to be addressed in order to provide clinicians and their patients with greater diagnostic certainty, and hence reduce inappropriate labelling and the potential psychological harm that may accompany misdiagnosis.
引用
- Skiba MA, Islam RM, Bell RJ, et al. Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018. PMID: 30059968. doi:10.1093/humupd/dmy022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。